2026 Webinar: Navigating NL Market Access: Your Strategic, Clinical, and Economic Roadmap to Reimbursement Success
26.03.2026 15:00-16:00 (CET)
Join us for a focused, practical session that serves as a guide to the increasingly complex Dutch reimbursement landscape and equips your team with the strategic knowledge needed to build a successful ZIN submission.
Drawing on deep expertise across NL market access strategy, HTA evidence requirements, and health-economic modelling, David and Jeanni walk you through the key stakeholders, pathways, and decision points that define success in the Netherlands — from early planning all the way through to reimbursement.
Why Attend: With ZIN submissions demanding rigorous clinical and economic evidence as part of a well-defined market access strategy, pharma teams must navigate a complex web of players, pathways, and timelines while aligning global and local deliverables. Submissions frequently fall short when evidence, clinical claims and positioning are misaligned, or economic models fail to meet NL-specific analytical standards. This session gives you the roadmap to get it right — from the first feasibility assessment to the final dossier.
Key Takeaways:
NL Market Access Landscape: A clear overview of the key players (ZIN, VWS, ZN, and more), the intramural and extramural pathways to reimbursement, and how NL timelines align with EMA milestones — so you always know your next step in the process.
ZIN Evidence Requirements: Understand exactly what ZIN expects clinically and economically — from clinical positioning, stakeholder planning, and GRADE assessment, to what it takes to build an economic model of sufficient quality that moves you to price negotiation.
Your NL Access Roadmap: A practical, timeline-driven guide to what needs to happen and when — covering PICO mapping, publication and stakeholder strategy, model and dossier planning, and how to align your local NL activities with your global program.
Speakers:
David Smalbrugge
Our Senior Lead for HEOR at GIPAM, based in the Hague, specializing in the complexity of the Dutch market access landscape. With six years of professional experience, he has successfully developed over 30 reimbursement dossiers in Netherlands.
At GIPAM he is responsible for leading and conducting projects in NL HTA and market access, including dossier writing, model adaptation, and strategic consultancy, guide clients through the reimbursement process at Zorginstituut Nederland.
David has a BSc in Medicine from the University of Leiden and a MSc in Health Economics, Policy, and Law from the Erasmus University in Rotterdam.
Jeanni van Loon
Jeanni is a senior life-sciences leader with over 25 years of experience in health economics and market access. She specializes in guiding Dutch pharma and biotech companies from early feasibility through successful pricing and reimbursement (P&R).
She develops integrated strategies that align clinical, economic, and PRO data with payer requirements, ensuring robust, evidence-based dossiers through RWE. With deep knowledge of the Dutch health system, Jeanni manages FT, FE, and BIA dossiers and acts as a strategic liaison with the Ministry of Health, ZIN, and other key stakeholders. Having led over 100 HEOR projects, she has a proven track record of securing reimbursement for innovative therapies.
With a background in physical therapy and an MSc from Erasmus University, Jeanni combines analytical expertise with cross-functional leadership. Her extensive payer network and interim management experience make her a trusted partner for achieving sustainable market access in the Netherlands.